Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

Stem Cell Therapeutics Provides Corporate Update

Published: Monday, January 20, 2014
Last Updated: Monday, January 20, 2014
Bookmark and Share
Company provides six-month corporate update.

Stem Cell Therapeutics Corp. has provided the following six-month corporate update:

• Pilot non-human primate tolerability studies have been completed using SIRPaFc, Stem Cell Therapeutics’ proprietary CD47 antagonist. Three separate human SIRPaFc proteins, possessing different Fc regions with varying levels of effector function, were evaluated in a repeat-dose regimen in cynomolgus macaques. Safe dosing levels, substantially above the anticipated human therapeutic dose, were established for each drug candidate. Greater tolerability was observed to correlate with decreasing effector function. Anemia and thrombocytopenia were the primary adverse events observed, which in most cases were asymptomatic and reversible.

These studies, while preliminary in nature, provided firm support for moving the SIRPaFc program forward into the next development phase. In parallel with conducting the manufacturing activities and toxicology studies typically associated with the IND-enabling phase of drug development, the company will significantly amplify its preclinical efficacy studies. This will be critical in order to uncover the full potential of this promising immune checkpoint inhibitor and to expand its use in the treatment of both solid and liquid tumors.

• Preclinical SIRPaFc efficacy data in an acute myeloid leukemia xenograft model was recently reported at the 55th Annual Meeting of the American Society of Hematology (ASH). SIRPaFc was shown to promote potent anti-leukemic responses at low doses. When combined with the non-human primate tolerability data, this indicates a wide therapeutic window. For details on the ASH presentation please consult our website at

• On December 13, 2013, the company completed a $33 million private placement, principally with participation from experienced U.S. healthcare institutional investors. Importantly, this substantial financing, one of the largest by a Canadian biopharmaceutical company last year, was primarily driven by the strength and promise of the SIRPaFc technology. Its proceeds will allow the company to execute an optimal development program over the next three years, which will include manufacturing, formal toxicology testing, as well as clinical studies in cancer patients.

• Dosing in the investigator-driven Phase I multicenter dose-escalation study (50mg-350mg) with tigecycline in patients with relapsed or refractory acute myeloid leukemia (AML) is nearing completion. Dosing has advanced to the 350mg cohort, a dose level that greatly exceeds the 100mg dose approved for anti-infective use and is well within the range of doses that have demonstrated anti-cancer activity in published preclinical studies. Patient recruitment has been slowed by the submission of a protocol amendment.

The cost of this study has been covered by the academic sponsor. As the exclusive licensee of this technology, the company continues to monitor the progress of the trial and anticipates its completion in 2014. Following a thorough evaluation of the clinical data and the program’s commercial potential the company will decide on an appropriate path forward.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT to Provide Update on CD47 Program at the 2014 AACR Annual Meeting
Announcing a key difference between SIRPaFc and other CD47-blocking agents.
Friday, April 04, 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Adds US industry veterans with broad financial and clinical expertise.
Tuesday, March 11, 2014
Stem Cell Therapeutics Announces Resignation of Director
Mr. David Allan has resigned from Company’s board of directors.
Thursday, January 30, 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Thursday, January 30, 2014
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.
Friday, December 20, 2013
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to its Board of Directors
Provides update on $33 million offering.
Wednesday, December 18, 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation
Company receives drug designation for the use of tigecycline to treat AML.
Friday, November 01, 2013
Stem Cell Therapeutics Acquires Complementary Antibody Program
The company has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a).
Thursday, October 17, 2013
Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase
Stem Cell Therapeutics Corp. announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase.
Monday, September 09, 2013
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
SCT Licenses Exclusive Rights to Clinical Cancer Stem Cell Program
Corporate refocusing mission completed.
Friday, April 19, 2013
SCT Announces Joint-Venture Agreement with Reneu and Nexgen
Company to move the combined technologies into clinical trials with a target of clinical initiation in 2014.
Wednesday, February 20, 2013
SCT Announces Agreement with Trillium for Merger
Continuing Stem Cell Therapeutics' commitment to expansion.
Wednesday, February 06, 2013
Stem Cell Therapeutics Announces Agreement with UHN and MaRS Innovation
Building on the continued strength of Canadian stem cell research.
Thursday, November 08, 2012
Scientific News
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
CRI Identifies Emergency Blood-formation Response
Researchers report that when tissue damage occurs, an emergency blood-formation system activates.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos